Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain.” The patent covers the company’s machine learning–based platform for analyzing magnetic resonance spectroscopy (MRS) data, which is central to its Nociscan cloud-based platform.
Nociscan converts complex MRS spectral data into clinically actionable insights to help physicians distinguish between painful and non-painful discs in the spine. The newly issued patent strengthens Aclarion’s ability to scale by protecting its use of AI in future platform versions to further automate biomarker identification, accelerate report generation, and reduce manual quality reviews. According to the company, this capability will enable consistent, reproducible outputs across imaging systems and sites, representing a key step toward broader clinical adoption.
Brent Ness, Chief Executive Officer of Aclarion, stated, “This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice. By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.”
The patent specifically covers machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized classifications associated with pain-related conditions. It also includes AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts. This expands Aclarion’s intellectual property portfolio to 64 issued and pending patents worldwide, reinforcing its strategy to build a differentiated, software-driven platform in the large and underserved chronic low back pain market.
Chronic low back pain affects approximately 266 million people globally. When used alongside other diagnostic tools, clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated. The patent can be read here. For more information about Aclarion and Nociscan, visit www.aclarion.com.
